*** RETAINED DUPLICATE: THIS CASE WAS ALSO PREVIOUSLY REPORTED AS GENENTECH CASE = 
INITIAL INFORMATION FOR THIS SPONTANEOUS CASE WAS RECEIVED ON 21 SEPTEMBER 2010 FROM A
HEMATOLOGIST AND FROM A POSTER PRESENTATION TO THE "MABTHERA OLYMPICS" AND 
CONCERNS A 52 YEARS OLD MALE PATIENT WHO EXPERIENCED FATAL PROGRESSIVE MULTIFOCAL 
LEUKOENCEPHALOPATHY WHILE TREATED WITH RITUXIMAB (MABTHERA) FOR DIFFUSE LARGE B CELL 
NON-HODGKIN'S LYMPHOMA.
NO CONCURRENT CONDITION AND NO RELEVANT MEDICAL HISTORY WERE REPORTED.
CONCOMITANT MEDICATIONS INCLUDED CYTARABINE AND MEFLOQUINE.  NO PAST DRUGS WERE 
REPORTED.
ON AN UNSPECIFIED DATE IN 2009, THE PATIENT WAS DIAGNOSED WITH CARCINOMA OF THE 
NASOPHARYNX TREATED BY SURGERY AND IRRADIATION.  ON AN UNKNOWN DATE IN MARCH 2010, 
THE PATIENT WAS DIAGNOSED WITH DIFFUSE LARGE B CELL NON-HODGKIN'S LYMPHOM AND 
STARTED TREATMENT WITH CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE AND VINCRISTINE 
(ROUTE, DOSE. FORM AND FREQUENCY UNKNOWN).  ON AN UNKNOWN DATE INJUNE 2010, THE 
TREATMENT WITH CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE AND VINCRISTINE WAS 
DISCONTINUED.  ON 16 JUNE 2010, THE PATIENT RECEIVED TREATMENT WITH INTRAVENOUS 
RITUXIMAB 375 MG ONCE IN THREE WEEKS (ROUTE AND FORM UNKNOWN).  ON AN UNSPECIFIED 
DATE, THE MRI BRAIN SHOWED CONSISTENT MULTIPLE WHITE MATTER LESIONS, THE HAEMOGLOBIN 
WAS 12 G/DL AND WHITE BLOOD CELL COUNT WAS 5800/ML.  ON 26 JUNE 2010, THE PATIENT 
DEVELOPED FATAL PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY.  ON AN UNKNOWN DATE, 
THE PATIENT DIED.
THE THERAPY WITH RITUXIMAB WAS DISCONTINUED.
THE REPORTER THE ASSESSED THE FATAL PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY TO 
BE RELATED TO THE RITUXIMAB.
ADDITIONAL INFORMATION HAS BEEN REQUESTED.
ADDITIONAL INFORMATION RECEIVED ON 11 OCTOBER 2010.
REPORTER INFORMATION UPDATED.
Print Time: 24-MAY-2016 07:56 AM If a field is blank, there is no data for that field Page 275 of 570
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
CONCOMITANT MEDICATION INCLUDED DEXAMETHASONE.  ON AN UNSPECIFIED DATE, THE PATIENT 
WAS DIAGNOSED WITH NASOPHARINGX NEOPLASM.  ON AN UNSPECIFIED DATE, IN OCTOBER 2009, HE
UNDERWENT SURGICAL REMOVAL OF THE TUMOUR AND IRRADIATION FOR NASOPHARINGX 
NEOPLASM.  PATIENT DID NOT HAD HISTORY OF HIV, BONE MARROW OR SOLID BONE TRANSPLANT, 
OPPORTUNISTIC INFECTIONS, CNS PATHOLOGY (CNS LUPUS OR CNS LYMPHOMA) AND COMPLICATION
OF PREVIOUS IMMUNOSUPPRESSIVE AND/ OR CHEMOTHERAPY.  IT WAS UNKNOWN WHETHER THE 
PATIENT HAD IMMUNODEFICIENCY, CHRONIC VIRAL INFECTION, HERPES SIMPLEX, HERPES ZOSTER 
AND CMV PNEUMOCYSTIC CARINII PNEUMONIA.
ON AN UNSPECIFIED DATE, IN FEBRUARY 2010, THE PATIENT WAS DIAGNOSED WITH DIFFUSED B CELL 
NON HODGKIN'S LYMPHOMA STAGE IV (STOMACH, LUNG, KIDNEYS).  IT WAS REPORTED THAT BRAIN 
MRI WAS NOT PERFORMED AT BASELINE.  ON 10 FEBRUARY 2010, THE PATIENT STARTED THERAPY 
WITH INTRAVENOUS CYCLOPHOSPHAMIDE 1300 MG 1 DAY, INTRAVENOUS DOXORUBICIN 90 MG 1 DAY 
AND INTRAVENOUS VINCRISTINE 2 MG 1 DAY.  HE WAS TREATED WITH SIX CYCLES OF 
CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE AND VINCRISTINE (CHOP) CHEMOTHERAPY.  ON 06
JULY 2010, PATIENT'S IGM WAS 67 MG/DL, IGG WAS 842 MG/DL, ANC WAS3400 /UL AND WBC COUNT 
WAS 5800 /UL (NORMAL RANGE NOT PROVIDED).  ON 16 JUNE 2010, SEVENTH CYCLE 
CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE AND VINCRISTINE (CHOP) WITH RITUXIMAB WAS 
ADMINISTERED.  ON THE SAME DAY, CYCLOPHOSPHAMIDE, DOXORUBICIN AND VINCRISTINE THERAPY 
WAS STOPPED.  (b) (6)  DAYS AFTER THE LAST CHEMOTHERAPY CYCLE THE PATIENT PRESENTED WITH 
ALTERED GENERAL CONDITION, DROWSINESS, DISORIENTATION, CONFUSION, INCOHERENT SPEECH, 
HEADACHE AND PHOTOPHOBIA.  HIS NEUROLOGICAL EXAMINATION REVEALED SLOW SPEECH, 
BRADIPSYCHIA, MOTOR AUTOMATISM, MYOCLONIA ARMS, HAND GRIP REFLEX, MARKED HYPOTONIA 
FOR LOWER LIMBS, AND SPHINCTERIAN INCONTINENCE.  AUTOPSY WAS NOT PERFORMED. 
NO FURTHER INFORMATION WAS PROVIDED.
Additional information received on 18/Aug/2014, following information added tot he case: Source changed from 
spontaneous to Literature spontaneous, Reporter added. Suspect drugs and concomitant drugs entries modified. 2 
literature references added.
This case cross linked to AER1450992 (logically deleted).